Skip to main
GHRS

GHRS Stock Forecast & Price Target

GHRS Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

GH Research PLC's stock has seen an increase of approximately 22%, driven by positive developments regarding its mebufotenin therapies for Treatment-Resistant Depression (TRD), particularly the inhalable candidate GH001, which has shown rapid efficacy and good safety profiles in early stages. Following the FDA's lifting of the clinical hold on GH001, the company is positioned to initiate a global Phase 3 program by 2026, suggesting a strong pathway towards commercialization. Analysts are increasingly optimistic about GH001's long-term sales potential, with estimates projecting over $1.4 billion at peak in TRD alone, bolstered by favorable pricing expectations that align with competitive offerings such as Spravato.

Bears say

GH Research PLC faces significant risks that contribute to a negative outlook on its stock, primarily stemming from potential delays in progressing to Phase III trials due to regulatory hurdles and alignment issues with the FDA. Additionally, the company's reliance on the efficacy and safety of its proprietary mebufotenin products in larger clinical studies raises concerns about unforeseen safety signals, as well as the challenges associated with market adoption due to its unique mode of administration compared to competitors. With no revenue-generating products and the inherent difficulties in developing treatments for neuropsychiatric conditions, GH Research's need for ongoing financing compounds the risks related to achieving manufacturing standards, regulatory approval, and successful commercialization in a competitive landscape.

GHRS has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GH Research PLC and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GH Research PLC (GHRS) Forecast

Analysts have given GHRS a Strong Buy based on their latest research and market trends.

According to 7 analysts, GHRS has a Strong Buy consensus rating as of Apr 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GH Research PLC (GHRS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.